# Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas

> **NCT03262116** · PHASE2,PHASE3 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 20 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Humalog
- **DRUG:** Novolog
- **DRUG:** BC222 insulin lispro
- **DEVICE:** Bionic Pancreas

## Key facts

- **NCT ID:** NCT03262116
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-19
- **Primary completion:** 2019-07-23
- **Final completion:** 2019-07-23
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Devices are not available
- **Last updated:** 2022-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03262116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03262116, "Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03262116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*